Drug Trial Radar · NCT02514213
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Jul 2015
Primary completion
Dec 12, 2017
Study completion Dec 12, 2017
Sponsor
- Lead sponsor
- Inovio PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
Conditions
- Prostate Cancer
Interventions
2mg INO-5150 and electroporation device CELLECTRA®-5PBiological
2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
8.5mg INO-5150 and electroporation device CELLECTRA®-5PBiological
8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5PBiological
2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5PBiological
8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
Electroporation using CELLECTRA®-5PDevice
Electroporation device CELLECTRA®-5P
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of INO-5150 alone or with INO-9012 delivered via IM EP ( Incidence of adverse events, Injection site reactions, Changes in safety laboratory parameters)Time frame: 72 weeks
- Antigen specific immune response of INO-5150 alone or with INO-9012 delivered via IM EPTime frame: 72 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Chesapeake Urology Research Associates
Baltimore, Maryland
Karmanos Cancer Institute
Detroit, Michigan
GU Research Network, LLC/ Urology Cancer Center
Omaha, Nebraska
Weill Cornell Medical College
New York, New York
University of North Carolina Lineberger Cancer Center
Chapel Hill, North Carolina
Cleveland Clinic
Cleveland, Ohio
Sidney Kimmel Cancer Center - Thomas Jefferson University
Philadelphia, Pennsylvania
UPMC
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.